Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanded protocadherin-1 usage reveals a broader hantavirus entry landscape.

bioRxiv : the preprint server for biology·2026
Same author

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

EMBO molecular medicine·2026
Same author

Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening.

Journal of experimental & clinical cancer research : CR·2026
Same author

The Deubiquitinating Enzyme Otub2 Modulates Pancreatic Beta-Cells Function and Survival.

Frontiers in bioscience (Landmark edition)·2026
Same author

Dissecting endometrial cancer complexity in response to standard and targeted therapies.

Cell death & disease·2025
Same author

PNKP targeting engages the autophagic machinery through STING and STAT3 to potentiate ferroptosis and chemotherapy in TNBC.

Redox biology·2025

Related Experiment Video

Updated: Oct 23, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Accelerating AXL targeting for TNBC therapy.

Lohit Khera1, Sima Lev1

  • 1Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, Israel.

The International Journal of Biochemistry & Cell Biology
|August 17, 2021
PubMed
Summary

Targeting the AXL receptor tyrosine kinase shows promise for treating various cancers. AXL inhibition may enhance efficacy when combined with other cancer therapies, particularly for triple-negative breast cancer (TNBC).

Keywords:
AXLCombination therapiesRTK signalingTNBCTargeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.4K

Related Experiment Videos

Last Updated: Oct 23, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The TAM receptor tyrosine kinase AXL plays a crucial role in cancer progression.
  • AXL is implicated in tumor-promoting activities such as metastasis and drug resistance.
  • AXL is a potential therapeutic target for both hematological and solid tumors.

Purpose of the Study:

  • To review the therapeutic potential of targeting AXL in cancer treatment.
  • To explore the outcomes of AXL inhibition alone and in combination with other therapies.
  • To emphasize the role of AXL in triple-negative breast cancer (TNBC).

Main Methods:

  • Mini-review of existing scientific literature on AXL.
  • Analysis of AXL's involvement in tumorigenic processes.
  • Discussion of combination therapy strategies involving AXL targeting.

Main Results:

  • AXL is integral to cell migration, invasion, epithelial-mesenchymal transition (EMT), and stemness.
  • Targeting AXL demonstrates potential benefits in overcoming cancer metastasis and drug resistance.
  • AXL inhibition may synergize with chemotherapy, radiotherapy, immunotherapy, and targeted therapy.

Conclusions:

  • AXL is a significant therapeutic target in oncology.
  • Combined therapeutic strategies involving AXL inhibition show promise for various cancers.
  • AXL targeting is particularly relevant for treating triple-negative breast cancer (TNBC).